

**ZOONO GROUP LIMITED
(ASX: ZNO)**

**ASX ANNOUNCEMENT - 19 October 2026
Quarterly Report and Company Update**

Continuing progress

Zoono Group Limited (**Company**) (ASX: ZNO) today releases its Appendix 4C for the quarter ending 30 September 2026. In conjunction with that release, Zoono provides the following quarterly activities report to update shareholders and the market on developments during the quarter and the Company's outlook.

Together with its strategic partner OSY Group Limited (**OSY**), the Company has continued to make further progress in commercialising its shelf-life extension products and technologies, and in other niche areas.

Shelf-life extension program

United Kingdom

Regional in-store trials with three major retailers are due to commence in October, covering strawberries and raspberries across both domestic and import produce. The trial programs, in punnets supplied by the Company's exclusive UK packaging partner, will run for between 8 to 20 weeks with final rollout decisions to follow. This follows the build-up of substantial positive data from numerous earlier smaller trials.

Equally importantly in demonstrating the scope for the coating technology, a broader trial program is being developed in conjunction with one of the major retailers across additional fresh produce categories. The Company anticipates other retailers to follow this initiative.

Engagements continue with multiple other retailers, ranging from early engagements to commercial discussions.

South Africa

Orders under the Company's exclusive agreement with South Africa's leading producer of large-format corrugated packaging are continuing in line with the first-year volume schedule, with the expectation of future consistent recurring purchases. An in-store trial involving tomatoes in coated board punnets with a leading premium South African retailer is scheduled to commence in October or November.

Application and shelf-life trials of coated plastic punnets for table grapes (for the export market) have been successfully completed with a leading plastic manufacturer and two major grape producers. The Company is targeting commercial rollout in 2027.

Australia

Following a successful trial on soft fruit with a supplier to Australian retailers, direct engagement with all three major retailers has commenced, with the initial focus following the UK model of first targeting soft fruits and then expanding to other categories.

A full-container export trial with a carrot grower is now in planning. This follows on from a successful first round of trials.

In parallel, discussions are progressing with manufacturers of corrugated board packaging.

Europe and Other Markets

Multiple trial programs are underway with food producers across soft fruit, tomatoes and salads. The Company is also exploring further partnership and commercial opportunities in the European Union and other key target geographies in the Americas, Africa and Asia, reflecting the global applicability of the Company's technology.

Other Niche Application

As a side bar to the shelf-life extension program, the Company has successfully completed a range of trials with commercial partners across a broad range of other niche applications over the past 18 months. These trials have demonstrated both the scope of application and the unique characteristics of the Zoono–OSY solution. It is the Company's intention to expand commercial rollouts into alternative niche categories alongside its packaging partners and directly with end-user customers as the platform matures.

Shipping Containers

Through OSY, and following successful commercial trials in 2025, Zoono products are now being used for the coating of shipping containers carrying fresh produce from South Africa and Namibia to international markets. Commercial programs are in place with four South African fruit exporters, with further exporters in discussion.

Approvals for use of the Company's products are also in place with three of the world's largest container shipping lines and apply globally across their fleets. Order volumes are being discussed.

The expansion of this business into other countries and shipping companies represents another opportunity for a recurring revenue stream from sales of the Company's products.

Adjacent and Linked Revenue Streams

R&D development projects are underway in further adjacent and complementary business lines including:

- Cut flowers – application of the Company's products and technology to flower sleeves to reduce wastage in the cut flower supply chain; and
- Synergistic shelf-life applications – this initiative involves the use of the Company's products in combination with other complementary shelf-life extension technologies.

Outlook

Cash receipts for the Quarter were NZ\$736K. While down NZ\$236K compared to Q4 of FY26, the result was a substantial increase (up NZ\$495K) on the PCP.

Zoono is positive that its strategy is working and, while progress is slower than expected, it is confident that it will benefit from materially increased commercial activity over the coming periods flowing from the conclusion of many of the trial programs, the scaling of deliveries under existing exclusive packaging contracts, the expansion of its business collaborations and, lastly, but equally importantly, the broadening of its business into new application categories.

Summary of Q4 Expenditure

Related party payments of NZ\$115,000 included in the following Appendix 4C were directors' fees (including amounts paid to the executive director) for services rendered.

Expenditure incurred during the quarter on business activities was primarily on staff costs (NZ\$90K), product manufacturing (NZ\$97K) and administration and corporate overheads (NZ\$635K). Other material expenditure included advertising and marketing (NZ\$21K) and interest and research and development (NZ\$11K).

For updates on what is happening globally on a day-to-day basis, follow Zoono Global on:
LinkedIn at: www.linkedin.com/company/zoono/

Instagram: <https://www.instagram.com/zoonoglobal/>

Twitter: <https://twitter.com/zoonoGlobal>

YouTube: <https://www.youtube.com/channel/UCva7oGloBRdAaFnwOzAHjLw>

Newsletters: <https://zoono.co.nz/pages/newsandmedia/>

This announcement has been authorised and approved for release to ASX by the Board of Zoono Group Limited.

For further information, please contact:

Zoono Group Limited

Paul Hyslop

Group MD

M: +64 21 659 977

E: paul.hyslop@zoono.com

Paul Ravlich

Group CFO

M: +64 21 075 9176

E: paul.ravlich@zoono.com

About Zoono

Zoono Group Limited is a global biotech company that develops, manufactures, and distributes a suite of scientifically validated, long-lasting and environmentally friendly antiviral and antibacterial solutions. Zoono's mission is to improve health and well-being through innovative, safe, non-toxic and durable germ protection.

Zoono produces sprays, wipes and foams suited for skin care, surface sanitisers, and mould remediation treatments. The products are based on the 'Zoono molecule', a unique molecule that bonds to any surface and inhibits the ability of microbes to bind to the surface including bacteria, viruses, algae, fungi, and mould.

Together with its strategic partner OSY Group Limited (OSY), the Company developed a ZXT speciality range of products and has continued to make significant progress commercialising its shelf-life extension products and technologies across multiple geographies and produce categories.

Zoono's products have received numerous regulatory approvals and Zoono's technology claims are supported by independent testing conducted in laboratories worldwide. Zoono is headquartered in New Zealand and its products are available globally.

To learn more, please visit: www.zoono.com.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Zoono Group Limited (ZNO)

ABN

73 006 645 754

Quarter ended ("current quarter")

30 September 2026

Consolidated statement of cash flows	Current quarter \$NZ'000	Year to date (3 months) \$NZ'000
1. Cash flows from operating activities		
1.1 Receipts from customers	736	736
1.2 Payments for		
(a) research and development	(6)	(6)
(b) product manufacturing and operating costs	(97)	(97)
(c) advertising and marketing	(21)	(21)
(d) leased assets	-	-
(e) staff costs	(90)	(90)
(f) administration and corporate costs	(635)	(635)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	-	-
1.5 Interest and other costs of finance paid	(2)	(2)
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	-	-
1.8 Other (provide details if material)	-	-
1.9 Net cash from / (used in) operating activities	(115)	(115)

2. Cash flows from investing activities		
2.1 Payments to acquire or for:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	-	-
(d) investments	-	-
(e) intellectual property	-	-
(f) other non-current assets	-	-

Consolidated statement of cash flows		Current quarter \$NZ'000	Year to date (3 months) \$NZ'000
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	-	-

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings and leases	(65)	(65)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	Net cash from / (used in) financing activities	(65)	(65)

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	267	267
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(115)	(115)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	-

Consolidated statement of cash flows		Current quarter \$NZ'000	Year to date (3 months) \$NZ'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(65)	(65)
4.5	Effect of movement in exchange rates on cash held	(10)	(10)
4.6	Cash and cash equivalents at end of period	77	77

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$NZ'000	Previous quarter \$NZ'000
5.1	Bank balances	77	267
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	77	267

6.	Payments to related parties of the entity and their associates	Current quarter \$NZ'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	115
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-
<i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i>		

7.	Financing facilities <i>Note: the term "facility" includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	Total facility amount at quarter end \$NZ'000	Amount drawn at quarter end \$NZ'000
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	-	-
7.4	Total financing facilities	-	-
7.5	Unused financing facilities available at quarter end		-
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		

8.	Estimated cash available for future operating activities	\$NZ'000
8.1	Net cash from / (used in) operating activities (item 1.9)	(115)
8.2	Cash and cash equivalents at quarter end (item 4.6)	77
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	77
8.5	Estimated quarters of funding available (item 8.4 divided by item 8.1)	0.67
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>		
8.6	If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1	Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
	Answer: No, the Company has signed material contracts and received orders that it is looking to supply over the next two quarters and, as the Company has net stock inventories of NZ\$5.2M, it expects in most instances to be able to use current inventories to materially reduce the cash outlay of cost of goods sold.	
8.6.2	Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
	Answer: Yes, the Company has available further funding lines, if required, and is also able to look at further placements or a rights issue.	
8.6.3	Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
	Answer: Yes, with the expected receipts from customers over the next two quarters, the Company fully expects to be able to continue its operations and to meet its business objectives.	
<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>		

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 19 October 2026

The Board of Zoono Group Limited

Authorised by:
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – e.g. Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.